Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 2/20 | 0.50 |
| ▸ | TSHR | P16473 | 1/20 | 0.50 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | THRB | P10828 | 1/20 | 0.42 |
| ▸ | DYRK1A | Q13627 | 2/20 | 0.39 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.39 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.39 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.39 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.39 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.39 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.39 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.39 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.39 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.39 |
| ▸ | HDAC9 | Q9UKV0 | 1/20 | 0.39 |
| ▸ | HDAC5 | Q9UQL6 | 1/20 | 0.39 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28720956 | 0.72 | L3MBTL1 (0.55) | RAB9ATSHRL3MBTL1KDM4EKMT2A | |
| SCHEMBL2400349 | 0.72 | KMT2A (0.41) | RAB9ATSHRL3MBTL1KDM4EKMT2A | |
| SCHEMBL22182815 | 0.71 | BUB1 (0.40) | L3MBTL1KMT2ABCHEMEN1HTR6 | |
| SCHEMBL28721669 | 0.71 | L3MBTL1 (0.58) | RAB9ATSHRL3MBTL1KDM4EKMT2A | |
| SCHEMBL2768807 | 0.70 | RAB9A (0.66) | RAB9ATSHRL3MBTL1KDM4EKMT2A | |
| SCHEMBL8685355 | 0.69 | L3MBTL1 (0.55) | RAB9ATSHRL3MBTL1KDM4EKMT2A | |
| SCHEMBL10267835 | 0.69 | TSHR (0.55) | RAB9ATSHRL3MBTL1KDM4EKMT2A | |
| SCHEMBL31668328 | 0.69 | L3MBTL1 (0.55) | RAB9ATSHRL3MBTL1KDM4EKMT2A | |
| SCHEMBL1247821 | 0.68 | TSHR (0.54) | RAB9ATSHRL3MBTL1KDM4EKMT2A | |
| SCHEMBL31435512 | 0.67 | RAB9A (1.00) | RAB9ATSHRL3MBTL1KDM4EKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7626026-B2 | Pyrrolo-indole and pyrrolo-quinoline derivatives as prodrugs for tumour treatment | UNIVERSITY OF BRADFORD (GB) | 2009-12-01 | — | — | US | disclosed |
| US-7626026-B2 | Pyrrolo-indole and pyrrolo-quinoline derivatives as prodrugs for tumour treatment | UNIVERSITY OF BRADFORD (GB) | 2009-12-01 | — | — | US | disclosed |
| EP-1409480-B1 | PYRROLO-INDOLE AND PYRROLO-QUINOLINE DERIVATIVES AS PRODRUGS FOR TUMOUR TREATMENT | UNIV LONDON PHARMACY (GB) | 2007-11-14 | — | — | EP | disclosed |
| US-20040157873-A1 | Pyrrolo-indole and pyrrolo-quinoline derivatives as prodrugs for tumour treatment | INCANTHERA LIMITED (GB) | 2004-08-12 | — | — | US | disclosed |
| EP-1409480-A1 | PYRROLO-INDOLE AND PYRROLO-QUINOLINE DERIVATIVES AS PRODRUGS FOR TUMOUR TREATMENT | THE SCHOOL OF PHARMACY, UNIVERSITY OF LONDON (GB) | 2004-04-21 | — | — | EP | disclosed |
| WO-2002068412-A1 | PYRROLO-INDOLE AND PYRROLO-QUINOLINE DERIVATIVES AS PRODRUGS FOR TUMOUR TREATMENT | SCHOOL OF PHARMACY, UNIVERSITY OF LONDON (GB) | 2002-09-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040157873-A1 | Pyrrolo-indole and pyrrolo-quinoline derivatives as prodrugs for tumour treatment | CYP1B1, TOP1, CYP1A1 | RAB9A 1819/4885TSHR 4126/4885L3MBTL1 2292/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.